Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery
Standard
Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. / Huttenlocher, Stefan; Sehmisch, Lena; Schild, Steven E; Blank, Oliver; Hornung, Dagmar; Rades, Dirk.
in: ANTICANCER RES, Jahrgang 34, Nr. 10, 10.2014, S. 5589-92.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery
AU - Huttenlocher, Stefan
AU - Sehmisch, Lena
AU - Schild, Steven E
AU - Blank, Oliver
AU - Hornung, Dagmar
AU - Rades, Dirk
N1 - Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
PY - 2014/10
Y1 - 2014/10
N2 - BACKGROUND/AIM: To develop a tool for estimating the risk of developing new cerebral lesions in 69 melanoma patients receiving radiosurgery for 1-3 cerebral metastases.PATIENTS AND METHODS: Ten factors were investigated: lactate dehydrogenase (LDH), radiosurgery dose, age, gender, performance status, maximum diameter, location and number of cerebral lesions, extra-cranial spread, time between melanoma diagnosis and radiosurgery. Two factors, number of lesions and extra-cranial spread, were included in the tool. Scoring points were achieved by dividing the 6-month rate of freedom from new cerebral lesions by 10.RESULTS: Sum scores were 9, 11, 12 or 14 points. Six-month rates of freedom from new brain metastases were 28%, 63%, 59% and 92% (p=0.002). Three prognostic groups were designed: A (9 points), B (11-12 points) and C (14 points). Freedom from new cerebral lesion rates were 28%, 60% and 92% (p<0.001).CONCLUSION: Group A and B patients should be considered for additional whole-brain radiotherapy (WBRT).
AB - BACKGROUND/AIM: To develop a tool for estimating the risk of developing new cerebral lesions in 69 melanoma patients receiving radiosurgery for 1-3 cerebral metastases.PATIENTS AND METHODS: Ten factors were investigated: lactate dehydrogenase (LDH), radiosurgery dose, age, gender, performance status, maximum diameter, location and number of cerebral lesions, extra-cranial spread, time between melanoma diagnosis and radiosurgery. Two factors, number of lesions and extra-cranial spread, were included in the tool. Scoring points were achieved by dividing the 6-month rate of freedom from new cerebral lesions by 10.RESULTS: Sum scores were 9, 11, 12 or 14 points. Six-month rates of freedom from new brain metastases were 28%, 63%, 59% and 92% (p=0.002). Three prognostic groups were designed: A (9 points), B (11-12 points) and C (14 points). Freedom from new cerebral lesion rates were 28%, 60% and 92% (p<0.001).CONCLUSION: Group A and B patients should be considered for additional whole-brain radiotherapy (WBRT).
KW - Aged
KW - Aged, 80 and over
KW - Brain Neoplasms
KW - Combined Modality Therapy
KW - Cranial Irradiation
KW - Female
KW - Humans
KW - Male
KW - Melanoma
KW - Middle Aged
KW - Prognosis
KW - Radiosurgery
KW - Retrospective Studies
KW - Treatment Outcome
M3 - SCORING: Journal article
C2 - 25275060
VL - 34
SP - 5589
EP - 5592
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 10
ER -